Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals

Strategic Insights -

A new study published in the Journal of Managed Care & Specialty Pharmacy has examined the real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals. The research, conducted by investigators at Memorial Sloan-Kettering Cancer Center, analyzed data from the Premier Healthcare Database to explore patient characteristics, length of hospital stay, and incidence of cyto-kine release syndrome among patients who initiated teclistamab in US hospital settings.

Key Takeaways:

  • The study included 413 patients with confirmed multiple myeloma who received at least one teclistamab administration in a hospital setting between November 1, 2022, and September 21, 2023.
  • The median age of the patients was 69 (32-89) years, with 47.5% of patients aged at least 70 years.
  • Most patients were male (56.4%), White (63.4%), and non-Hispanic (86.0%), with 24.2% identifying as Black.
  • At the index hospital encounter, 47.9% of patients presented with anemia, 40.0% with peripheral neuropathy, and 35.8% with renal impairment/failure.
  • Among 302 patients who completed step-up dosing, 91.4% completed SUD in a single inpatient admission with a mean length of stay of 8.7 days.
  • Cyto-kine release syndrome (CRS) was observed in 31.8% of patients, with 28.5% experiencing CRS-related symptoms, including fever (15.2%) and hypotension (10.3%).
  • Most patients with a complete SUD period received dexamethasone (97.0%), acetaminophen (93.7%), and diphenhydramine (78.5%) at any time during the SUD period.

Statistics:

  • Median age of patients: 69 (32-89) years
  • Proportion of patients aged at least 70 years: 47.5%
  • Proportion of patients who were male: 56.4%
  • Proportion of patients who were White: 63.4%
  • Proportion of patients who were non-Hispanic: 86.0%
  • Number of patients with anemia: 198 (47.9%)
  • Number of patients with peripheral neuropathy: 164 (40.0%)
  • Number of patients with renal impairment/failure: 148 (35.8%)
  • Number of patients who completed step-up dosing: 302
  • Mean length of stay for patients who completed step-up dosing: 8.7 days
  • Proportion of patients who experienced cyto-kine release syndrome: 31.8%
  • Proportion of patients who experienced CRS-related symptoms: 28.5%
  • Number of patients who received dexamethasone: 295 (97.0%)
  • Number of patients who received acetaminophen: 275 (93.7%)
  • Number of patients who received diphenhydramine: 237 (78.5%)

Sources:

  • Real-world Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma In Us Hospitals: an Analysis Using the Premier Healthcare Database. Journal of Managed Care & Specialty Pharmacy, 2025;31(8):772-781.
  • NewsRx. New Multiple Myeloma Data Have Been Reported by Investigators at Memorial Sloan-Kettering Cancer Center (Real-world Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma In Us Hospitals: an Analysis ...). Cardiovascular Week. October 20, 2025; p 530.